跳至主要内容
临床试验/DRKS00016583
DRKS00016583招募中未知

An open label, prospective, randomized, crossover, monocentric clinical trial to assess safety and performance of a retinal imaging laser eyewear system in patients with visual impairment caused by corneal diseases. - RILEW-01

QD Laser Deutschland GmbH0 个研究点目标入组 21 人开始时间: 2019年2月4日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
21

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • 1. Male or female outpatients, aged = 18 and = 85 years
  • 2. Visually impaired according to legal definition (BCVA = 0.3)
  • 3. Corneal opacities/diseases according to at least one of the following ICD-10 codes:
  • H16.- Keratitis
  • H17.- Corneal scars and opacities
  • H18.- Other disorders of the cornea
  • S05.- Injury of eye and orbit
  • T26.- Burn and corrosion confined to eye and adnexa
  • T81.- Complications of procedures
  • T86.0 - Bone-marrow transplant rejection
  • 4. Best corrected visual acuity (BCVA) = 0.2 in the study eye
  • 5. Difference between BCVA and VA assessed with retinometer =2 lines in the study eye
  • 6. Ability to converse, read, and write fluently in German
  • 7. Written informed consent
  • 8. Subjects able and willing to attend all scheduled visits and comply with all study procedures and obligations

排除标准

  • Eligible subjects must not meet any of the following exclusion criteria:
  • 1. Significant function loss within the study eye due to diseases other than listed in inclusion criterion No. 3 or due to any surgery to the posterior part of the eye
  • 2. Subject unable to tolerate the RETISSA eyewear
  • 3. Intended corneal transplantation in the study eye in the next four months
  • 4. Central or peripheral diseases of the vestibular system (e.g. Ménière´s Disease, vestibular migraine, benign paroxysmal positional vertigo, etc.) that cause a clinically significant vertigo
  • 5. Previous application of pharmaceuticals with retinal toxicity,
  • a. that have reached the cumulative doses in the patient or
  • b. where treatment of the patient has not been stopped within the time frame of 5 half-lives (of the respective pharmaceutical) prior to the screening visit or
  • c. for which treatment of the patient needs to be continued after screening
  • 6. Diagnosed depression
  • 7. Risk of non-compliance with study procedures (e.g. lack of cooperation)
  • 8. Being immediate family of the investigator or trial staff, defined as the investigator's/staff's spouse, parent, child, grandparent, or grandchild
  • 9. Conditions, which, in the opinion of the investigator, would not allow save participation in this study (drug addiction, alcohol abuse, etc.)
  • 10. Females currently pregnant or breast-feeding
  • 11. Participation in any study involving an investigational drug or device within the past 30 days or ongoing participation in a study with an investigational drug or device
  • 12. Persons who are accommodated in an institution as a result of an official or judicial order

研究者

相似试验